BEIJING: (HRNW) Animal tests of a potential COVID-19 vaccine being developed by Chinese researchers show it triggers an immune response against the novel coronavirus, offering some promise as it goes into early-stage human trials, according to a peer-reviewed study.
ARCoV is a messenger RNA vaccine which uses technology similar to candidates being developed by Moderna and BioNtech and Pfizer. It is the second potential COVID-19 vaccine that China’s military-backed research unit has moved into clinical trials.
Results of trials of ARCoV in mice and monkeys, published in the peer-reviewed medical journal Cell on Thursday, show both single and two-dose inoculations induced strong antibody and T-cell responses against several COVID-19-causing virus strains.
However, researchers conducting the trial cautioned they were not yet able to see how long the ARCoV-induced antibodies might last or how strong their protection might be to other strains that cause COVID-19 but were not tested in the study.
Be the first to comment on "Chinese COVID-19 vaccine candidate shows promise in animal tests"